Urs Wiedemann is a panelist on a workshop entitled “Let’s get personal: Advances in precision medicine are changing the way we identify and treat disease.”
CRA is a silver sponsor for this annual conference.
For more information on this event, click here.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...